Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tiragolumab, an antibody targeting TIGIT.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ieramilimab, an antibody targeting LAG-3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Favezelimab, an antibody targeting LAG-3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Fianlimab, an antibody targeting LAG-3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Relatlimab, an antibody targeting LAG-3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tremelimumab, an antibody targeting CTLA-4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ipilimumab, an antibody targeting CTLA-4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Benmelstobart, an antibody targeting PD-L1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Envafolimab, an antibody targeting PD-L1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cosibelimab, an antibody targeting PD-L1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Adebrelimab, an antibody targeting PD-L1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sugemalimab, an antibody targeting PD-L1.